AstraZeneca PLC
AZN
$75.71
$0.540.72%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 12.02B | 11.49B | 11.42B | 10.88B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 12.02B | 11.49B | 11.42B | 10.88B |
| Cost of Revenue | -- | 2.30B | 2.06B | 1.92B | -- |
| Gross Profit | -- | 9.73B | 9.44B | 9.50B | -- |
| SG&A Expenses | -- | 4.89B | 4.44B | 5.05B | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -131.00M | -70.00M | -784.00M | -- |
| Total Operating Expenses | -- | 9.99B | 8.96B | 8.81B | 8.19B |
| Operating Income | -- | 2.03B | 2.53B | 2.60B | 2.69B |
| Income Before Tax | -- | 897.00M | 1.65B | 2.09B | -- |
| Income Tax Expenses | -- | -62.00M | 274.00M | 268.00M | -- |
| Earnings from Continuing Operations | -- | 959.00M | 1.38B | 1.82B | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 1.00M | -4.00M | -2.00M | -- |
| Net Income | -- | 960.00M | 1.37B | 1.82B | 1.80B |
| EBIT | -- | 2.03B | 2.53B | 2.60B | 2.69B |
| EBITDA | -- | 2.93B | 3.76B | 3.83B | 3.92B |
| EPS Basic | 0.62 | 0.62 | 0.89 | 1.17 | 1.16 |
| Normalized Basic EPS | -- | 0.70 | 0.90 | 0.90 | -- |
| EPS Diluted | 0.61 | 0.61 | 0.88 | 1.17 | 1.16 |
| Normalized Diluted EPS | -- | 0.70 | 0.89 | 0.89 | -- |
| Average Basic Shares Outstanding | -- | 1.55B | 1.55B | 1.55B | -- |
| Average Diluted Shares Outstanding | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B |
| Dividend Per Share | -- | 1.97 | 0.00 | 0.93 | -- |
| Payout Ratio | -- | 0.21% | -- | -- | -- |
